Cancer Genomic Medicine - Immunotherapy Response


While immunotherapy (IT) represents a new and exciting weapon in the fight against cancer, only a subset of cancer patients treated with IT respond beneficially. In melanoma, where IT has seen most of its success, the success rate remains at ~40%. There remains much that we don't understand about the mechanisms for effectively marshalling the patient's own immune system to fight the tumor.  By integrating biological expertise with compuational models on genetic and genomic data, we are working to understand the mechanisms of IT response and better predict which patients would most benefit from IT treatments.